mrr pvt. Ltd.

Global Insulin Glargine Market Outlook 2016-2021

Press Release   •   Feb 20, 2017 17:33 IST

p { margin-bottom: 0.25cm; line-height: 120%; }a:link { }

This report provides detailed analysis of worldwide markets for Insulin Glargine from 2011-2016, and provides extensive market forecasts (2016-2021) by region/country and subsectors. It covers the key technological and market trends in the Insulin Glargine market and further lays out an analysis of the factors influencing the supply/demand for Insulin Glargine, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert). Pharmacokinetically, it resembles basal insulin secretion of non-diabetic pancreatic beta cells. Sometimes, in type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. In the absence of endogenous insulintype 1 diabetes, depleted type 2 (in some cases) or latent autoimmune diabetes of adults in late stageinsulin glargine needs the support of fast acting insulin taken with food to reduce the effect of prandially derived glucose.

GCC's report, Global Insulin Glargine Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Insulin Glargine market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Insulin Glargine market areSanofi (France), Novo Nordisk (Demark), Eli Lilly (USA), Tonghua Dongbao (China), Gan & Lee (China).

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Insulin Glargine industry has been provided.

Download Sample Copy of This Report at: http://www.marketresearchreports.biz/sample/sample/776351